MeiraGTx jumps after promising data from dry mouth therapy study

MeiraGTx Holdings

07/12/2021 16:40

** Shares of gene therapy co  MGTX.O  up ~14% at $19.36,
their biggest one-day percentage gain in more than a month 
    ** Co says data from an early-stage study in seven
participants showed its gene therapy helped relieve symptoms of
radiation-induced xerostomia or dry mouth  urn:newsml:reuters.com:*:nGNX9xdxPY 
    ** Dry mouth or xerostomia is one of the most common
complications during and after radiotherapy for head and neck
cancer
    ** While the main goal of the trial was safety, MGTX says
the trial provides encouraging evidence of the emerging clinical
profile of the treatment 
    ** AAV-hAQP1 appears safe and well-tolerated with no serious
adverse events reported, co says
    ** Co plans to start a mid-stage study of AAV-hAQP1 in the
second half of next year 
    ** Stock has risen ~28% YTD 
    
    

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))